Alkermes (ALKS) is down -6.7%, or -$2.08 to $28.93.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes issues response to Avadel announcement
- Avadel receives $23 per share acquisition proposal from Lundbeck
- Alkermes price target lowered to $45 from $55 at Deutsche Bank
- Alkermes: Hold Rating Amid Mixed Trial Results and Uncertain Market Position
- Morgan Stanley sees Centessa’s ORX750 as ‘best-in-class’ after competitor data